



## I. Skin Cancers

### a. Epidemiologic/Correlative

**UCI 18-05\*\*Pending**  
Molecular epidemiology on gender difference in melanoma risk (Liu-Smith)

**UCI 09-17**  
Biology of Human Melanocytes and Keratinocytes (Meyskens)

**UCI 14-25**  
Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)

**UCI 16-01**  
(PAINT)-Pathway Analyses for Individualized Network Therapeutics for Cancer (Nelson)

**UCI 15-40**  
Prospective and Retrospective Study of Outcomes for Patients with Malignant Melanoma (Yamamoto)

**UCI 17-53\*\*Pending**  
Exploring Nevi's Molecular Mechanisms of Growth Arrest (De Feraudy)

### b. Screening/Diagnostic

**UCI 11-30**  
Skin imaging with Technologies in Development (Kelly)

**UCI 13-13**  
Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopy and multispectral imaging (Kelly)

**UCI 15-08**  
Spectral comparison between Spatially Modulated Quantitative Spectroscopy (SMoQS) and Polarization Sensitive Hyperspectral Multimode Dermoscopy for the purpose of skin compositional analysis (Kelly)

## II. Cutaneous Melanoma

### a. Screening/Diagnostic

**UCI 16-82** DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study #4 (Yamamoto)

**UCI 14-05** Multi-Center Evaluation of Oncogenesis via Spectral Analysis with the Melanoma Advanced Imaging Dermoscope (mAID) (Linden/Kelly)

### b. Metastatic: Unresectable Not Previously Treated

#### i. BRAF Mutated Only

**UCI 17-73**  
A Sequential 2-arm, Open-label Phase 1 Study to Evaluate the Effects of Encorafenib in Combination with Binimetinib on the Pharmacokinetics of Losartan, Midazolam, Caffeine, Omeprazole, and Dextromethorphan Administered in a Cocktail Approach and on the Pharmacokinetics of Rosuvastatin in Patients with BRAF V600-mutant Unresectable or Metastatic Melanoma or Other Advanced Solid Tumors (Fruehauf)

#### ii. BRAF Wild-Type Only

**UCI 16-102-Suspended-**  
A Phase III, Open-Label, Multicenter, Two Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma (Fruehauf)

**III. Cutaneous T-Cell Lymphoma (CTCL)**

**a. Screening/Diagnostic**

**UCI 16-37\*\*Pending**  
 Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome (Pinter-Brown)

**b. Therapeutic**

**UCI 16-46**  
 A Phase 1 Dose-Ranging Study to Investigate the Safety, Tolerability and Pharmacokinetics of MRG-106 Following Local Intratumoral, Subcutaneous, and Intravenous Administration in Subjects with Various Lymphomas and Leukemias (Pinter-Brown)

**UCI 17-36**  
 A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma (Pinter-Brown)

**UCI 17-82**  
 A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA (Pinter-Brown)

**IV. Miscellaneous & Phase 1 Clinical Trials**

**ECOG-EAY131**  
 Molecular Analysis for Therapy Choice (MATCH) (Bota)

**UCI 16-96**  
 A Phase 1 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)

**SWOG S1609 (CIRB) DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)**

**UCI 17-50**  
 A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)